OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Gopal on Future Research Directions in Non-ccRCC

April 26th 2024

Nikhil A. Gopal, MD, discusses future research directions for the treatment of various renal cell carcinoma histologies.

Dr Maxwell on Strategies to Optimize Genetic Testing in Metastatic Prostate Cancer

April 26th 2024

Kara N. Maxwell, MD, PhD, discusses strategies to optimize the utility of genetic testing to better inform decision-making in prostate cancer treatment.

Dr Kopetz on the Background of the KRYSTAL-1 Trial in KRAS G12C+ mCRC

April 26th 2024

Scott Kopetz, MD, PhD, FACP, discusses using adagrasib plus cetuximab in patients with metastatic colorectal cancer harboring KRAS G12C mutations.

Dr Nanda on the Evolution of CDK4/6 Inhibitor Treatment in HR+/HER2– Breast Cancer

April 26th 2024

Rita Nanda, MD, discusses the evolution of treatment with CDK4/6 inhibitors in patients with hormone receptor-positive/HER2-negative breast cancer.

Dr Fedorov on the Use of Quizartinib vs Midostaurin in FLT3+ AML

April 26th 2024

Kateryna Fedorov, MD, discusses considerations when deciding between quizartinib and midostaurin for patients with FLT3-mutated AML.

Dr Nye on Future Treatment Directions in HER2+ Breast Cancer Brain Metastases

April 26th 2024

Lauren E. Nye, MD, discusses future directions for the treatment of patients with HER2-positive breast cancer with brain metastases.

Dr Jurcic on the Use of JAK Inhibitors in Myelofibrosis Management

April 26th 2024

Joseph G. Jurcic, MD, discusses the use of JAK inhibitors in the management of myelofibrosis.

Dr Eroglu on Future Steps for Assessing Ceritinib Plus Trametinib in Metastatic Melanoma

April 26th 2024

Zeynep Eroglu, MD, discusses future steps for assessing ceritinib in combination with trametinib in patients with metastatic melanoma.

Dr Pantin on the Evolving Treatment Paradigm in PNH

April 25th 2024

Jeremy M. Pantin, MD, discusses the evolution of the PNH treatment paradigm and agents that are available or being investigated in this disease.

Dr Hafez on the Design of the FeDeriCa Trial in HER2+ Early Breast Cancer

April 25th 2024

Maria Hafez, MD, discusses the design of, and outcomes from, the phase 3 FeDeriCa trial in patients with HER2-positive early breast cancer.

Dr Eroglu on the Safety Profile of Ceritinib Plus Trametinib in Advanced Melanoma

April 25th 2024

Zeynep Eroglu, MD, discusses the safety profile of ceritinib plus trametinib in pretreated metastatic melanoma.

Dr Jagannath on the Potential Role for Linvoseltamab in R/R Multiple Myeloma

April 25th 2024

Sundar Jagannath, discusses the potential role for linvoseltamab in relapsed/refractory multiple myeloma.

Dr Jain on Unmet Needs in the Treatment of Low- and High-Risk MDS

April 25th 2024

Akriti Jain, MD, discusses unmet needs in patients with low- and high-risk myelodysplastic syndromes.

Dr Singh on Unmet Medical Needs in Lung Cancer Treatment

April 25th 2024

Raj Singh, MD, discusses unmet medical needs in the treatment of patients with lung cancer.

Dr Konecny on PROs With Mirvetuximab Soravtansine in Advanced Ovarian Cancer

April 25th 2024

Gottfried Konecny, MD, discusses patient-reported outcomes from the phase 3 MIRASOL trial in platinum-resistant ovarian cancer.

Dr Chamie on the FDA Approval of N-803 Plus BCG for BCG-Unresponsive NMIBC

April 24th 2024

Karim Chamie, MD, discusses the FDA approval of nogapendekin alfa plus BCG for patients with BCG-unresponsive non–muscle invasive bladder cancer.

Dr Lattanzi on the Investigation of PARP Inhibitor Combinations in mCRPC

April 24th 2024

Mike Lattanzi, MD, discusses clinical trials that have evaluated the use of PARP inhibitor–based combination regimens in patients with mCRPC.

Dr Eskander on Pembrolizumab Plus Chemo in Advanced/Recurrent Endometrial Cancer

April 24th 2024

Ramez N. Eskander, MD, discusses overall survival data for pembrolizumab plus chemotherapy in advanced/recurrent endometrial cancer.

Dr Ignatz-Hoover on the Evolving Use of Blinatumomab in ALL

April 24th 2024

James Ignatz-Hoover, MD, PhD, discusses the implications of utilizing blinatumomab to treat acute lymphoblastic leukemia.

Dr. Tiwari on Ongoing Research in HER2+/HER2-Low Breast Cancer

April 24th 2024

Shruti Tiwari, MD, discusses efforts to address unmet needs through ongoing research in HER2-positive and HER2-low breast cancer.